Thrombophilic factors do not predict outcomes in renal transplant recipients under prophylactic acetylsalicylic acid.
A cohort of recipients of renal transplant after 2000 (N=310) was prospectively screened on the day of transplantation and 1 month later for a panel of 11 thrombophilic factors to assess their effect on posttransplant outcomes. All patients received prophylactic acetylsalicylic acid, started before transplantation. The rate of thromboembolic events or acute rejection episodes during the first posttransplant year (primary composite endpoint) was 16.7% among patients free of thrombophilic factor (N=60) and 17.2% in those with >or=1 thrombophilic factor (N=250) (p>0.99). The incidence of the primary endpoint was similar among patients free of thrombophilic factors and those with >or=2 (N=135), or >or=3 (N=53) factors (16.3% and 15.1% respectively; p=1) and in patients who remained thrombophilic at 1 month (15.7%; p=0.84). None of the individual thrombophilic factor present at the day of transplantation was associated with the primary endpoint. The incidence of cardiovascular events at 1-year, serum creatinine at 1-year, 4-year actuarial graft and patient survival were not influenced by the presence of >or=1 thrombophilic factor at baseline (p=NS). In conclusion, the presence of thrombophilic factors does not influence thromboembolic events, acute rejection, graft or patient survival in patients transplanted after 2000 and receiving prophylactic acetylsalicylic acid.
Renal Transplantation Clinic, Laboratory of Hematology, Department of Clinical Pathology, ULB-Erasme Hospital, Brussels, Belgium. lghisdal@yahoo.com
L
L
Ghisdal
N
N
Broeders
K-M
KM
Wissing
A
A
Saidi
T
T
Bensalem
J
J
Mbaba Mena
A
A
Lemy
W
W
Wijns
O
O
Pradier
A-D
AD
Hoang
D
D
Mikhalski
V
V
Donckier
P
P
Cochaux
H
H
El Housni
M
M
Abramowicz
P
P
Vereerstraeten
D
D
Abramowicz
D000208:Acute Disease; D000328:Adult; D001241:Aspirin / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000517:prevention & control; D015331:Cohort Studies; D003404:Creatinine / Q000097:blood; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006084:Graft Rejection / Q000097:blood / Q000209:etiology; D006085:Graft Survival / Q000187:drug effects; D006801:Humans; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000502:physiology; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D015996:Survival Rate; D013923:Thromboembolism / Q000209:etiology; D019851:Thrombophilia / Q000097:blood / Q000209:etiology* / Q000517:prevention & control*; D013997:Time Factors; D016896:Treatment Outcome
D005343:Fibrinolytic Agents; D003404:Creatinine; D001241:Aspirin